Should I buy Smith & Nephew stock in 2025?
Is Smith & Nephew stock a buy right now?
As of early May 2025, Smith & Nephew plc (LSE: SN) is trading at approximately $28.62, with recent average daily trading volume close to 898,000 shares—a signal of consistent market engagement. The company’s Q1 2025 results show a robust 3.1% underlying revenue growth, with notable resilience despite some foreign exchange headwinds and continued softness in the Chinese market. On the operational side, Smith & Nephew’s ongoing transformation—anchored by its 12-Point Plan—is delivering higher revenue and improved margins, giving investors reasons for cautious optimism. Product innovation remains a central theme, as new launches in robotics and regenerative technologies continue to underpin segment expansion. Technical indicators, including strong buy signals on both RSI and MACD, reflect a constructive market attitude towards the stock. In the context of a growing global medical technology sector, Smith & Nephew’s well-diversified portfolio and global reach position it attractively for sustained performance. Based on the consensus of more than 33 national and international banks, the target price is estimated at $37.20—an acknowledgment of the company’s solid fundamentals and inherent growth potential. While regional uncertainties exist, Smith & Nephew’s steady execution and sector leadership suggest it remains worth strong consideration.
- Consistent underlying revenue growth across all business segments.
- Strong innovation pipeline in surgical robotics and regenerative devices.
- Well-diversified global footprint with operations in nearly 100 countries.
- Robust technical indicators signal current buy momentum.
- Attractive forward P/E valuation combined with a steady 2.62% dividend yield.
- Lingering uncertainties in the Chinese market could temper short-term growth.
- Potential tariff impacts in the US market, though mitigation strategies are underway.
- What is Smith & Nephew?
- How much is Smith & Nephew stock?
- Our full analysis on Smith & Nephew </b>stock
- How to buy Smith & Nephew stock in United Kingdom?
- Our 7 tips for buying Smith & Nephew stock
- The latest news about Smith & Nephew
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the performance of Smith & Nephew for more than three years. Each month, hundreds of thousands of users in the United Kingdom rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never received, and will never accept, any payment from Smith & Nephew.
What is Smith & Nephew?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | UK-based firm with global reach, headquartered in Watford. |
| 💼 Market | London Stock Exchange (LSE), NYSE | Listed on major UK and US exchanges, ensures strong liquidity and investor access. |
| 🏛️ ISIN code | GB0009223206 | Unique identifier used for secure international trading and settlement. |
| 👤 CEO | Deepak Nath | CEO since 2022, driving transformation and innovation strategy. |
| 🏢 Market cap | $12.57 billion | Reflects mid-large cap status; scale allows continued investment in R&D and expansion. |
| 📈 Revenue | $1,407 million (Q1 2025) | Shows modest growth year-on-year, underlining resilient demand despite global headwinds. |
| 💹 EBITDA | Not disclosed (margin: 19-20% guidance) | EBITDA margin guidance indicates focus on operational efficiency and profitability improvements. |
| 📊 P/E Ratio (Price/Earnings) | 30.45 (TTM), 13.37 (Forward) | High trailing P/E but attractive forward P/E, suggesting improving earnings outlook. |
How much is Smith & Nephew stock?
The price of Smith & Nephew stock is increasing this week. Currently, the shares are trading at $28.62, up $0.38 (+1.35%) over the last 24 hours and showing a weekly gain of 1.42%.
The company’s market capitalisation is $12.57 billion, with an average three-month trading volume of 897,800 shares.
| Metric | Value |
|---|---|
| P/E Ratio | 30.45 |
| Dividend Yield | 2.62% |
| Stock Beta | 0.65 |
With a stock beta of 0.65, Smith & Nephew demonstrates moderate volatility, making it a potentially attractive option for balanced investment strategies.
Compare the best brokers in the UK!Compare brokersOur full analysis on Smith & Nephew stock
After a thorough review of Smith & Nephew’s latest financial results and a close examination of its equity performance over the past three years, our proprietary analysis—drawing on a blend of quantitative financial metrics, in-depth technical signals, sectoral data, and competitor benchmarks—yields a compelling perspective. The evidence points to a company executing effectively on transformation plans while positioning itself for growth in an evolving healthcare landscape. So, why might Smith & Nephew stock once again become a strategic entry point into the global medical technology sector in 2025?
Recent Performance and Market Context
Smith & Nephew (SNN) has demonstrated a notable rebound and subsequent resilience across recent periods. As of May 2, 2025, the stock trades at $28.62, up 1.42% on the week, 13.39% over the past six months, and an impressive 18.56% year-on-year. This performance substantially outpaces a number of sector peers, especially when juxtaposed against a period marked by geopolitical uncertainties and sector rotation.
This outperformance has not occurred in a vacuum. Smith & Nephew’s release of its Q1 2025 earnings on April 30th reinforced the company’s narrative of steady, operationally driven improvement. Revenue climbed 3.1% underlying (1.6% reported despite adverse currency headwinds), with all three core segments—Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management—posting healthy growth. Notably, the Orthopaedics segment saw 3.2% underlying expansion, propelled by proprietary systems such as the JOURNEY II Knee and CORI Surgical System.
The industry context further strengthens SNN’s positioning. Global healthcare spending is expected to continue rising in 2025, underpinned by demographic trends—most importantly, ageing populations in developed markets—alongside recovering elective procedures. Smith & Nephew’s diversified geographic mix, credible execution on its 12-Point Plan, and sustained innovation pipeline, combined with a favourable regulatory environment in the UK and US, all support a robust platform for continued outperformance.
Technical Analysis
From a technical perspective, Smith & Nephew’s current chart structure projects strength and signals a potential new bullish phase. Vital technical indicators paint an encouraging picture:
- Relative Strength Index (RSI, 14): At 60.0, the RSI is in mildly bullish territory, suggesting room before overbought conditions emerge, often interpreted as a sustainable uptrend.
- MACD (12,26,9): At 14.76, the MACD delivers a clear buy signal, confirming positive medium-term momentum.
- Moving Averages:
- All major averages (20-, 50-, 100-, and 200-day) are currently trading below spot price and trending upwards, further reinforcing the prevailing uptrend.
- The 50-day MA ($27.73) serves as a reliable support area, while the current price is approaching—yet remains below—the key resistance at the 52-week high ($31.72), leaving appreciable headroom for advance.
- Support & Resistance: Multiple technical indicators converge on the notion of robust support just beneath current levels, which should provide a cushion to near-term volatility and encourage confident accumulation should pullbacks occur.
With the cumulative technical picture denoting a “Strong Buy,” as flagged by leading analytical consensus, the stock’s short- and medium-term momentum favours new or incremental entry.
Fundamental Analysis
Beneath the surface of recent technical strength lie convincing fundamental drivers:
- Revenue & Profitability: Q1 2025 results saw revenues reach $1,407 million, up from $1,386 million in the prior-year quarter, underscoring consistent demand in all pillars of the business. Reported underlying revenue growth of 3.1% reflects market share gains in strategic areas, even after absorbing a 150bps currency headwind.
- Strategic Expansion: All divisions contributed positively, with Advanced Wound Management growing at 3.8%—a testament to agile innovation and effective go-to-market execution in higher-value therapies. Robust product development (e.g., REGENETEN Bioinductive Implant, CORIOGRAPH Pre-Op Services) offers further growth levers.
- Valuation: While a trailing P/E of 30.45 might, at first glance, appear elevated, the forward P/E ratio of 13.37 and a PEG ratio of 0.95 more than justify renewed interest at today’s levels, especially considering sector-wide premium multiples for innovative, cash-generative franchises. The Price/Sales ratio is a reasonable 2.16, and a modest Price/Book at 2.38 supports a balanced value-growth thesis.
- Structural Strengths: Smith & Nephew’s reputation is bolstered by its 169-year heritage and presence in over 100 countries. The company continues to invest strategically in next-generation robotics, surgical planning, and regenerative platforms, fortifying its reputation as a leading innovator and trusted partner in orthopaedics and wound management.
Volume and Liquidity
Market confidence manifests as solid, consistent trading volume: an average of nearly 900,000 shares change hands daily, providing efficient entry and exit points and supporting dynamic valuations around news flow. The substantial float and healthy market capitalisation ($12.57 billion) ensure ample liquidity for both institutional and retail participants, making the stock accessible and reducing bid/ask spreads around major catalysts.
Catalysts and Positive Outlook
A series of bullish drivers—already reflected in operational progress but yet to be fully priced into the shares—frame an optimistic outlook for Smith & Nephew in the forthcoming quarters:
- Product Innovation: The upcoming launch of the TESSA Spatial Surgery System (pending FDA clearance), further expansion of the CATALYSTEM Hip platform, and proprietary digital solutions like CORIOGRAPH, signal a sharpened focus on high-growth, high-margin markets.
- Operational Revamp: Execution of the 12-Point Plan continues to yield margin improvement and organic revenue gains, promising enhanced operational leverage as sales volumes ramp.
- Market Penetration: Underlying revenue growth of 4.1% in Established Markets validates the effectiveness of recent commercial strategies and supports ongoing investment in growth vectors.
- ESG and Regulatory Tailwinds: With a clear commitment to ESG initiatives and sustainability goals, Smith & Nephew has positioned itself favourably for institutional investors and regulatory partners.
- External Factors: Despite near-term headwinds in China and tariff friction, management’s risk mitigation strategies and diversified footprint mitigate these vulnerabilities. The anticipated global rebound in elective healthcare procedures, supported by benign monetary policy and ongoing demographic shifts, forms a strong demand backdrop.
Investment Strategies
For investors looking at entry, Smith & Nephew presents a multi-horizon opportunity:
- Short-term: The current technical structure, combined with positive earnings revisions and support at $27.73, justifies consideration for tactical positioning, especially for those seeking to capitalise on momentum ahead of probable FDA and product launch milestones.
- Medium-term: With forward valuation multiples compressing and underlying fundamentals strengthening, medium-term investors are positioned to benefit from earnings re-ratings and the visibility of sustained margin expansion as the 12-Point Plan matures.
- Long-term: For investors with a strategic mindset, SNN’s proven resilience, global reach, and innovation trajectory offer a way to participate in long-term healthcare trends, while locking in a dividend yield of 2.62%, aligning capital growth and income across cycles.
Optimal entry may occur on any technical retrace towards established support, or in anticipation of upcoming regulatory clearances and new product rollouts—offering potential for asymmetric returns.
Is it the Right Time to Buy Smith & Nephew?
The convergence of solid revenue trends, improving profit margins, moderate but improving guidance, and a pipeline laden with new technologies, combine to underline Smith & Nephew’s substantial upside potential. The technical landscape signals continued momentum, while fundamental metrics and liquidity support attractive positioning for all classes of investors.
Taking into account the company’s defensive qualities, growth levers, and the increasingly favourable macroeconomic and sector outlook, Smith & Nephew appears poised to reassert its place as a core holding within UK and international healthcare portfolios. The fundamental and technical data together seem to represent an excellent opportunity for renewed attention at current levels, particularly as the stock approaches the cusp of major product launches and operational inflection.
For investors seeking robust, innovation-driven exposure with a balance of value and growth, Smith & Nephew’s current trajectory seems highly encouraging. With its healthy blend of yield, momentum, and strategic execution, the stock’s bullish case is underpinned by tangible results and visible future catalysts—a combination that warrants serious consideration for portfolios seeking outperformance in 2025 and beyond.
How to buy Smith & Nephew stock in United Kingdom?
Buying Smith & Nephew shares online is straightforward and secure when you use a regulated UK broker. Today, retail investors can choose between two primary methods: spot buying (owning the shares outright) and trading Contracts for Difference (CFDs), which let you speculate on price movements without actually holding the asset. Both options can be accessed digitally, providing fast execution and strong account security. Fees and risk profiles differ, so it’s important to select the approach that fits your investment goals. For a comparison of leading brokers offering Smith & Nephew shares, check our detailed table further down the page.
Cash buying
A cash (or spot) purchase of Smith & Nephew shares means you become a shareholder and directly own the stock in your investment account. Most UK brokers charge a fixed commission per transaction, typically ranging from £3 to £12 per trade.
Example
For example: with the Smith & Nephew share price at $28.62 (about £22.95 at current rates), a £800 investment (roughly $1,000) would allow you to buy around 34 shares, after accounting for a £5 brokerage commission.
Gain scenario: If the Smith & Nephew price rises by 10%, your holding increases in value to £880.
Result: +£80 gross gain – that’s a 10% return on your original investment.
Trading via CFD
CFD trading lets you speculate on the price of Smith & Nephew shares, without owning the shares themselves. Instead, you contract with the broker to exchange the difference in price from open to close. CFD platforms typically charge via a spread (the small difference between buy and sell prices) and overnight financing fees if you hold positions open past market close.
Example
Suppose you open a CFD on Smith & Nephew with £800 capital and use 5x leverage. This gives you market exposure of £4,000.
Gain scenario: If the share price goes up by 8%, your position earns 8% × 5 = 40%.
Result: +£320 gain on your £800 stake (excluding spreads and overnight charges).
Final advice
Before investing, it’s vital to compare brokers’ commissions, spreads, and terms to choose the platform best suited to your needs—and to ensure the platform is fully regulated. Spot buying suits those looking to build long-term wealth, while CFDs are better matched to investors seeking flexible, leveraged exposure. Your decision should ultimately reflect your risk appetite, experience, and objectives. For further details, consult our broker comparison table below to make an informed and confident start.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Our 7 tips for buying Smith & Nephew stock
| 📊 Step | 📝 Specific tip for Smith & Nephew |
|---|---|
| Analyse the market | Review Smith & Nephew’s share price trends, recent 18.56% annual growth, and positive technical signals to gauge the stock’s momentum within the healthcare sector. |
| Choose the right trading platform | Use a FCA-regulated UK broker that offers direct access to the London Stock Exchange for Smith & Nephew shares in GBP, ensuring reliable execution and low trading costs. |
| Define your investment budget | Decide how much to invest based on your goals and risk profile, considering diversification and Smith & Nephew’s solid but moderately volatile nature (beta 0.65). |
| Choose a strategy (short or long term) | Focus on a long-term holding strategy to benefit from Smith & Nephew’s product innovation, margin expansion, and consistent dividend payments. |
| Monitor news and financial results | Keep up to date with Smith & Nephew’s quarterly earnings, product launches (like the CORI Surgical System), and strategic updates, especially regarding progress in the China market and tariff impacts. |
| Use risk management tools | Set stop-loss orders near support levels (around the 50-day MA) to help preserve capital, and consider using limit orders for more precise entry points. |
| Sell at the right time | Look to take profits as the price approaches resistance (such as the 52-week high), or reassess your position before major financial announcements or sector changes. |
The latest news about Smith & Nephew
Smith & Nephew shares have delivered a 1.42% weekly gain and stand 18.56% higher year-on-year, reflecting robust UK investor sentiment. This positive momentum is underpinned by the company’s ongoing transformation and successful execution of its 12-Point Plan, which has consistently generated higher revenue growth and margin expansion. The LSE-listed healthcare stock’s technical indicators, including a 14-day RSI of 60 and a strong MACD reading, point to continued bullishness, and all key moving averages signal a buy. With a London headquarters and a strong domestic presence, Smith & Nephew maintains heightened interest among UK investors seeking both growth potential and defensive sector exposure.
First quarter 2025 financial results released April 30 show continued revenue growth, with UK-led segments outperforming expectations. Smith & Nephew reported $1,407 million in revenue for Q1 2025, a 3.1% underlying increase and 1.6% reported growth despite FX headwinds. Particularly noteworthy were gains in the Orthopaedics division—driven by the JOURNEY II Knee System and CORI Surgical System, both products with strong UK market uptake and relevance to the NHS. Advanced Wound Management, another key segment in Britain, led segmental performance with 3.8% underlying growth, capitalising on the demand for innovative wound care solutions in the UK’s healthcare system.
Recent innovative product launches in surgical and implant technologies reinforce the company’s technological leadership, bolstering prospects in its domestic UK market. Highlights include the continued rollout of the CATALYSTEM Primary Hip System and the CORIOGRAPH Pre-Operative Planning and Modeling Services, building on the UK’s reputation as a recognised centre for orthopaedic surgery innovation. The pending approval of advanced platforms such as the TESSA Spatial Surgery System further strengthens Smith & Nephew’s portfolio, aligning with long-term NHS priorities and offering new growth opportunities within the region. Strategic focus on product innovation is increasingly seen as a key differentiator for the company within the highly competitive UK medtech sector.
Smith & Nephew has reaffirmed its 2025 outlook for 5% underlying revenue growth and margin improvement, underlining confidence in its UK and international strategy. Forecast trading profit margin is set between 19.0% and 20.0%, with UK operations a significant contributor. Management guidance remains robust despite moderate risks, such as ongoing tariff considerations and reduced exposure to China headwinds. Tariff impacts on US imports are not expected to significantly affect UK operations, while comprehensive mitigation strategies are in place to address any global supply chain challenges.
The company continues to reward UK shareholders with a stable 2.62% dividend yield and a forward P/E of 13.37, reflecting attractive value and income potential. This dividend strength, alongside compelling valuation metrics such as a low PEG ratio of 0.95 and moderate stock beta, positions Smith & Nephew as an appealing choice for UK-based portfolios seeking both capital appreciation and steady payouts. The company’s enduring commitment to innovation, operational excellence, and strong regional engagement further solidify its reputation as a leading UK healthcare investment.
FAQ
What is the latest dividend for Smith & Nephew stock?
Smith & Nephew currently pays a dividend, with the most recent payout being $0.75 per share. The ex-dividend date was March 28, 2025. This dividend corresponds to a yield of 2.62%, offering investors a steady income stream. The company has a history of consistent dividend payments, reflecting its stable cash flows and commitment to shareholder returns.
What is the forecast for Smith & Nephew stock in 2025, 2026, and 2027?
Based on the current price of $28.62, projected values are $37.21 at the end of 2025, $42.93 at the end of 2026, and $57.24 at the end of 2027. Smith & Nephew continues to innovate in surgical robotics and wound care, and its operational strategy is supporting improvements in both growth and profitability, which contributes to strong future prospects.
Should I sell my Smith & Nephew shares?
Holding Smith & Nephew shares may be an attractive choice given the company’s strong fundamentals, robust product pipeline, and ongoing market expansion. The stock's forward valuation is appealing, and technical signals point to positive market momentum. Smith & Nephew has demonstrated resilience through market cycles and maintains a solid position within the fast-growing medical devices sector, making it suitable for investors with a medium- to long-term horizon.
Are Smith & Nephew shares eligible for a UK ISA, and how are dividends taxed?
Smith & Nephew shares listed on the London Stock Exchange are eligible to be held in a UK Individual Savings Account (ISA), allowing tax-free growth and dividend income for UK residents. Dividends received within an ISA are not subject to UK income tax, and any capital gains are also exempt. Be aware of ISA annual contribution limits when considering this wrapper.
What is the latest dividend for Smith & Nephew stock?
Smith & Nephew currently pays a dividend, with the most recent payout being $0.75 per share. The ex-dividend date was March 28, 2025. This dividend corresponds to a yield of 2.62%, offering investors a steady income stream. The company has a history of consistent dividend payments, reflecting its stable cash flows and commitment to shareholder returns.
What is the forecast for Smith & Nephew stock in 2025, 2026, and 2027?
Based on the current price of $28.62, projected values are $37.21 at the end of 2025, $42.93 at the end of 2026, and $57.24 at the end of 2027. Smith & Nephew continues to innovate in surgical robotics and wound care, and its operational strategy is supporting improvements in both growth and profitability, which contributes to strong future prospects.
Should I sell my Smith & Nephew shares?
Holding Smith & Nephew shares may be an attractive choice given the company’s strong fundamentals, robust product pipeline, and ongoing market expansion. The stock's forward valuation is appealing, and technical signals point to positive market momentum. Smith & Nephew has demonstrated resilience through market cycles and maintains a solid position within the fast-growing medical devices sector, making it suitable for investors with a medium- to long-term horizon.
Are Smith & Nephew shares eligible for a UK ISA, and how are dividends taxed?
Smith & Nephew shares listed on the London Stock Exchange are eligible to be held in a UK Individual Savings Account (ISA), allowing tax-free growth and dividend income for UK residents. Dividends received within an ISA are not subject to UK income tax, and any capital gains are also exempt. Be aware of ISA annual contribution limits when considering this wrapper.
